News >

Expert Discusses Molecular Analysis and Treatment Options in Pediatric Ependymoma

Jason Harris
Published: Thursday, Jul 12, 2018

Santhosh A. Upadhyaya, MD

Santhosh A. Upadhyaya, MD
Among pediatric patients with ependymoma, investigators found no difference in 4-year survival by molecular subgroups, according to results from the SJYC07 trial presented at the 2018 ASCO Annual Meeting.

Among patients in the posterior fossa A (PF-A) subgroup, progression-free survival (PFS) was 73.7% ± 8.5% compared with 80% ± 20.7% in the supratentorial C11 or f95RELA-fused subgroup and 100% in the supratentorial YAP1-fused subgroup. Investigators concluded the differences were not significant (P = .40).

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Briefings™: Individualizing Treatment After Second-Line Therapy for Patients With mCRCAug 29, 20191.0
Community Practice Connections™: Immunotherapeutic Strategies with the Potential to Transform Treatment for Genitourinary CancersAug 29, 20191.0
Publication Bottom Border
Border Publication